FORM PTO-1449 — U.S. Dept. of Commerce, Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P1661R2C1	not yet assigned
Applicant	
Adams, Camellia et al.	
Filing Date	**Group**
08 Jul 2003	not yet assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
DB	* 1	5,654,407	05.08.97	Boyle et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
DB	* 2	WO 91/16353	31.10.91	PCT				
DB	* 3	WO 95/25167	21.09.95	PCT				
DB	* 4	WO 97/26010	24.07.97	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DB	* 5	Ahmad and Walsh, "Platelet membrane-mediated coagulation protease complex assembly" Trends in Cardiovascular Medicine 4(6):271-277 (1994)
	* 6	Ahmad et al., "Coagulation factor IX residues G_4-Q_{11} mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex" Biochemistry 37(6):1671-1679 (Feb 10, 1998)
	* 7	Ahmad et al., "High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11" Biochemistry 33(40):12048-12055 (Oct 11, 1994)
	* 8	Bach, R. R., "Initiation of Coagulation by Tissue Factor" CRC Critical Reviews in Biochemistry 23(4):339-368 (1988)
	* 9	Benedict et al., "Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model" Journal of Clinical Investigation 88(5):1760-1765 (Nov 1991)
	*10	Blackburn et al., "Anti-factor IX monoclonal antibody, BC2, is a potent antithrombotic agent" Blood (Abstract #1885) 90(Suppl. 1):424a-425a (1997)
	*11	Cheung et al., "Identification of the endothelial cell binding site for factor IX" Proc. Natl. Acad. Sci. USA 93(20):11068-11073 (Oct 1, 1996)
	*12	Cheung et al., "The binding of human factor IX to endothelial cells is mediated by residues 3-11" Journal of Biological Chemistry 267(29):20529-20531 (Oct 15, 1992)
	*13	Davie et al., "The Coagulation Cascade: Initiation, Maintenance, and Regulation" Biochemistry 30(43):10363-10370 (1991)
	*14	Di Scipio et al., "Activation of human factor IX (Christmas factor)" Journal of Clinical Investigation 61(6):1528-1538 (Jun 1978)
	*15	Figini et al., "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation" J. Mol. Biol. 239:68-78 (1994)
	*16	Fujikawa et al., "The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XI_a (activated plasma thromboplastin antecedent)" Biochemistry 13(22):4508-4516 (Oct 22, 1974)
	*17	Heimark and Schwartz, "Binding of coagulation factors IX and X to the endothelial cell surface" Biochemical & Biophysical Research Communications 111(2):723-731 (Mar 16, 1983)
	*18	Janeway et al. Immunobiology, Garland Press, 4th edition, London NY pps. 87 (1999)
DB	*19	Lewis et al Blood 56(4):608-614 (1980)

Examiner: David Blackwell — Date Considered: 4/15/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce	Atty Docket No.	Serial No.
	Patent and Trademark Office	P1661R2C1	not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT		Applicant	
(Use several sheets if necessary)		Adams, Camellia et al.	
		Filing Date	Group
		08 Jul 2003	not yet assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DB	*20	Lewis et al., "Isolation of CA++-dependent human antibodies to human factor IX" Circulation (abstract #1070) 62(4):III-279 (Oct 1980)
	*21	Liebman et al., "The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa" Journal of Biological Chemistry 262(16):7605-7612 (Jun 5, 1987)
	*22	Liebman, H., "The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX" European Journal of Biochemistry 212(2):339-345 (Mar 1, 1993)
	*23	Limentani et al. Hemostasis and Thrombosis Basic Principles and Clinical Practice, Chapter 5, Coleman et al. Eds., Third edition, Philadelphia:Lippincott Company (1994)
	*24	Mann et al., "Surface-dependent hemostasis" Seminars in Hematology 29(3):213-226 (Jul 1992)
	*25	Osterud and Rapaport, "Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation" Proc. Natl. Acad. Sci. USA 74(12):5260-5264 (Dec 1977)
	*26	Osterud et al., "Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI" Journal of Biological Chemistry 253(17):5946-5951 (Sep 10, 1978)
	*27	Pike et al., "Immunochemical characterization of a monoclonal γG4, λ human antibody to factor IX" Blood 40(1):1-10 (Jul 1972)
	*28	Prorok et al., "The entire γ-carboxyglutamic acid- and helical stack-domains of human coagulation factor IX are required for optimal binding to its endothelial cell receptor" International Journal of Peptide & Protein Research 48:281-285 (1996)
	*29	Rawala-Sheikh et al., "Role of γ-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation" Blood 79(2):398-405 (Jan 15, 1992)
	*30	Refino et al., "A Human Antibody That Binds to the γ-Carboxyglutamic Acid Domain of Factor IX is a Potent Antithrombotic In Vivo." Thrombosis and Haemostasis 82(3):1188-1195 (Sep 1999)
	*31	Reisner et al., "Immunochemical characterization of a polyclonal human antibody to factor IX" Blood 50(1):11-19 (Jul 1977)
	*32	Ryan et al., "Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding" Journal of Biological Chemistry 264(34):20283-20287 (Dec 5, 1989)
	*33	Sekiya et al., "Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions" Journal of Biological Chemistry 270(24):14325-14331 (Jun 16, 1995)
	*34	Spanier et al., "Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog" Journal of Thoracic & Cardiovascular Surgery 115(5):1179-1188 (May 1998)
	*35	Stenflo and Dahlback, "Vitamin K-Dependent Proteins" The Molecular Basis of Blood Diseases, Stamatoyannopoulos et al. eds., 2nd edition, Philadelphia, PA:Saunders pps. 565-598 (1994)
	*36	Suggett et al., "Use of phage display for the generation of human antibodies that neutralize factor IX function" Blood (abstract #2266) 92(10 suppl. 1):551a (Nov 15, 1998)
	*37	Sugo et al., "Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations" Thrombosis Research 58(6):603-614 (Jun 15, 1990)
	*38	Toomey et al., "The endothelial cell binding determinant of human factor IX resides in the γ-carboxyglutamic acid domain" Biochemistry 31(6):1806-1808 (Feb 18, 1992)
DB	*39	Wong et al., "Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis" Thrombosis and Haemostasis 77(6):1143-1147 (Jun 1997)

Examiner	Date Considered
David Blatchford	4/15/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 | U.S. Dept. of Commerce | Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P1661R2C1	not yet assigned
Applicant	
Adams, Camellia et al.	
Filing Date	**Group**
08 Jul 2003	not yet assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DB	*40	Yoshitake et al., "Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)" Biochemistry 24(14):3736-3750 (Jul 2, 1985)
DB	*41	Zhong et al., "Some human inhibitor antibodies interfere with factor VIII binding to factor IX" Blood 92(1):136-142 (Jul 1, 1998)

Examiner: David Blackwood | Date Considered: 4/15/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.